Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Leucine and Improved Erythroid Response

Doses used in studies

mg/day: 2,100 (median 2,100, IQR 2,100–2,100) — 1 study

Time to effect

Median: 9 months · IQR 9 months–9 months · Range 9 months–9 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
No significant adverse events were attributable to L-leucine.
from: L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackf

1 of 1 paper

L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry.
- 2020-10-06
- Clinical Trial · n = 55
- Pediatric blood & cancer 67(12)
- - Adrianna Vlachos
  - Evangelia Atsidaftos
  - Mohammad Lutfi Lababidi
  - Ellen Muir
  - Zora R Rogers
  - Waseem Alhushki
  - Jonathan Bernstein
  - Bertil Glader
  - Barbara Gruner
  - Helge Hartung
  - Christine Knoll
  - Thomas Loew
  - Grzegorz Nalepa
  - Anupama Narla
  - Arun R Panigrahi
  - Colin A Sieff
  - Kelly Walkovich
  - Jason E Farrar
  - Jeffrey M Lipton
- PubMed: 33025707
- DOI: 10.1002/pbc.28748
3 Insights on
- Improved Erythroid Response
- High evidence
- Clinical
Two subjects had a complete erythroid response and five had a partial response.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
700 mg/m^2 orally three times daily